“There’s not the clear-cut clinical evidence like physicians wanted, the products don’t stop the disease like the patients wanted, they’re never going to be as big a blockbuster as industry wanted and they don’t necessarily save money for Medicare [the federal health insurance scheme],” said Robert Przybelski, a geriatrician at UW Health in Madison, Wisconsin, where about 25 patients have been treated with the drug.'
https://www.ft.com/content/1e02c10c-f7c4-48e9-a6a4-774531b56350